Market Overview

Pfizer Announces EC Approval to Expand Use of Prevenar 13


Pfizer (NYSE: PFE) announced today that the European Commission has
approved expanding the use of the company's pneumococcal conjugate
vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine
[13-valent, adsorbed]), to older children and adolescents aged 6 to 17
years for active immunization for the prevention of invasive disease,
pneumonia and acute otitis media caused by vaccine-type Streptococcus
pneumoniae. Children in this age group who have not previously
received Prevenar 13 may receive a single dose of the vaccine.

“Prevenar 13 has been administered to millions of infants and young
children around the world and helps protect against the often fatal
effects of pneumococcal disease,” said Emilio Emini, Ph.D., chief
scientific officer, Vaccine Research, Pfizer. “As

See full press release

Posted-In: News Guidance Management M&A Global


Related Articles (PFE)

View Comments and Join the Discussion!